Movement Alert｜EVEREST MED Rises 5.8% in Regular Trading, Velsipity Domestic Production Application Accepted with Priority Review

Market Focus09-21

On September 21, EVEREST MED rose 5.8% in regular trading, trading at HK$29.28 per share, with turnover of HK$57.12 million.

On the news front, the company announced on September 17 that the NMPA's Center for Drug Evaluation has accepted the registration application for transferring Velsipity (etrasimod) production from overseas to domestic facilities, with the application included in the priority review program. Local production is expected to commence in 2027 with annual capacity of up to 50 million tablets, enhancing supply chain resilience and cost efficiency across China and Asia-Pacific markets.

Additionally, multiple positive catalysts have converged in recent weeks. The company's first cardiovascular drug Xinbituo was approved by NMPA in early September for acute PSVT treatment in adults, marking the first and only innovative therapy for this indication in over 30 years. The company reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, with adjusted profits turning positive. The chairman of the board also recently increased his holdings, reinforcing market confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171130638?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171130638","market":"us","top_or_hot":-1,"title":"Movement Alert｜EVEREST MED Rises 5.8% in Regular Trading, Velsipity Domestic Production Application Accepted with Priority Review","media":"Market Focus","content":"<p><p>On September 21, EVEREST MED rose 5.8% in regular trading, trading at HK$29.28 per share, with turnover of HK$57.12 million.</p><p>On the news front, the company announced on September 17 that the NMPA's Center for Drug Evaluation has accepted the registration application for transferring Velsipity (etrasimod) production from overseas to domestic facilities, with the application included in the priority review program. Local production is expected to commence in 2027 with annual capacity of up to 50 million tablets, enhancing supply chain resilience and cost efficiency across China and Asia-Pacific markets.</p><p>Additionally, multiple positive catalysts have converged in recent weeks. The company's first cardiovascular drug Xinbituo was approved by NMPA in early September for acute PSVT treatment in adults, marking the first and only innovative therapy for this indication in over 30 years. The company reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, with adjusted profits turning positive. The chairman of the board also recently increased his holdings, reinforcing market confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜EVEREST MED Rises 5.8% in Regular Trading, Velsipity Domestic Production Application Accepted with Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜EVEREST MED Rises 5.8% in Regular Trading, Velsipity Domestic Production Application Accepted with Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-21 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 21, EVEREST MED rose 5.8% in regular trading, trading at HK$29.28 per share, with turnover of HK$57.12 million.</p><p>On the news front, the company announced on September 17 that the NMPA's Center for Drug Evaluation has accepted the registration application for transferring Velsipity (etrasimod) production from overseas to domestic facilities, with the application included in the priority review program. Local production is expected to commence in 2027 with annual capacity of up to 50 million tablets, enhancing supply chain resilience and cost efficiency across China and Asia-Pacific markets.</p><p>Additionally, multiple positive catalysts have converged in recent weeks. The company's first cardiovascular drug Xinbituo was approved by NMPA in early September for acute PSVT treatment in adults, marking the first and only innovative therapy for this indication in over 30 years. The company reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, with adjusted profits turning positive. The chairman of the board also recently increased his holdings, reinforcing market confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1171130638","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171130638","pubTimestamp":1789955073,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 21, EVEREST MED rose 5.8% in regular trading, trading at HK$29.28 per share, with turnover of HK$57.12 million.On the news front, the company announced on September 17 that the NMPA's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"走势警报|珠穆朗玛峰常规交易上涨5.8%，Velsipity国内生产申请获优先审核","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On September 21, EVEREST MED rose 5.8% in regular trading, trading at HK$29.28 per share, with turnover of HK$57.12 million.On the news front, the company announced on September 17 that the NMPA's Center for Drug Evaluation has accepted the registration application for transferring Velsipity (etrasimod) production from overseas to domestic facilities, with the application included in the priority review program. Local production is expected to commence in 2027 with annual capacity of up to 50 million tablets, enhancing supply chain resilience and cost efficiency across China and Asia-Pacific markets.Additionally, multiple positive catalysts have converged in recent weeks. The company's first cardiovascular drug Xinbituo was approved by NMPA in early September for acute PSVT treatment in adults, marking the first and only innovative therapy for this indication in over 30 years. The company reported first-half revenue of RMB 1.148 billion, up 157% year-over-year, with adjusted profits turning positive. The chairman of the board also recently increased his holdings, reinforcing market confidence.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171130638","isCrawlerRequest":true}